Efficacy and safety of lacosamide in patients with erythromelalgia due to SCN9A gene mutation

Efficacy and safety of lacosamide in patients with erythromelalgia due to SCN9A gene mutation - Lacosamide for familial erythromelalgia

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs071180055

Enrollment

Registered

2019-03-18

Start date

2017-08-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Familial erythromelalgia

Interventions

The administration of lacosamide is maintained on 200 mg/ day, if the symptom do not improve, the dose is increased by 50 mg/day each week until 400 mg/day. In a case of Ccr under 30 ml/min, the dose

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Older than 15 years 2.A case of erythromelalgia due to SCN9A gene mutation 3.A case who consent to informed consent

Exclusion criteria

Exclusion criteria: 1.A case with severe liver dysfunction(greater than Child-Pug Score C)2.A case with significant ECG abnormality(second-degree atrioventricular block,Brugada symdrome) 3.A case who is considered by a doctor to be inappropriate for administration of lacosamide.

Design outcomes

Primary

Measure	Time frame
Amount of change in scoring below 16 weeks after starting lacosamide administration PI-NRS Pain Intensity Numerical Rating Scale	—

Secondary

Measure	Time frame
Amount of change in scoring of PI-NRS and DSIS. Change over time of blood test ( WBC, Hb, PLT, AST, ALT, BUN, Crea, LDH)	—

Contacts

Public ContactSayaka Yamguchi

University of the Ryukyus Hospital

sayaka-y@cs.u-ryukyu.ac.jp+81-98-894-1427

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026